Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BBI-355 |
| Trade Name | |
| Synonyms | BBI355|BBI 355 |
| Drug Descriptions |
BBI-355 is a selective inhibitor of CHK1, which potentially induces cytotoxicity in tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 3631, Ann Oncol (2023) 34 (Suppl_2): S477). |
| DrugClasses | CHK1 Inhibitor 18 |
| CAS Registry Number | 3017958-71-0 |
| NCIT ID | C200039 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BBI-355 | BBI-355 | 0 | 1 |
| BBI-355 + BBI-825 | BBI-355 BBI-825 | 0 | 1 |
| BBI-355 + Erlotinib | BBI-355 Erlotinib | 0 | 1 |
| BBI-355 + Futibatinib | BBI-355 Futibatinib | 0 | 1 |